Mast cell activation syndrome

​At present, there is no cure for any subtype of MCAS and there is a lack of studies evaluating the prognosis.[3]Weiler CR, Austen KF, Akin C, et al. AAAAI Mast Cell Disorders Committee Work Group report: Mast cell activation syndrome (MCAS) diagnosis and management. J Allergy Clin Immunol. 2019 Oct;144(4):883-96. https://www.jacionline.org/article/S0091-6749(19)31116-9/fulltext http://www.ncbi.nlm.nih.gov/pubmed/31476322?tool=bestpractice.com ​ In practice, the prognostic outcome will depend on reducing the frequency and severity of life-threatening anaphylaxis episodes, which in turn relies on:

• Avoidance of allergens or other triggers (if feasible)

• The patient’s compliance with advice on appropriate use of their epinephrine (adrenaline) auto-injector

• The success of venom immunotherapy (in relevant patient subgroups for whom this is indicated).

With appropriate maintenance treatment, the frequency and severity of MCAS acute episodes can be controlled and will tend to decrease over time. Therefore, the life expectancy for most patients who receive a diagnosis of MCAS appears unchanged although quality of life can be severely impaired.